BIRC5 and central nervous system cancer: CRAd-S-pk7 represents an innovative oncolytic adenovirus platform that utilizes neural stem cells (NSCs) as delivery vectors to penetrate the blood-brain barrier, while its tumor-specific survivin promoter restricts viral replication to survivin-overexpressing glioma cells.